Ironwood Pharmaceuticals Inc (IRWD)
Ironwood Pharmaceuticals, Inc. is a NASDAQ-listed common stock of a biotechnology company focused on developing and commercializing therapies for gastrointestinal and rare diseases in the United States and international markets. Its commercial portfolio includes linaclotide, marketed under the LINZESS and CONSTELLA names, for adults with irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric functional constipation. The company is also advancing IW-3300 for visceral pain conditions such as interstitial cystitis/bladder pain syndrome and endometriosis, and Apraglutide for short bowel syndrome in patients dependent on parenteral support and for acute graft versus host disease. Ironwood maintains strategic partnerships with AbbVie, AstraZeneca, and Astellas Pharma related to linaclotide. The company was incorporated in 1998, was formerly known as Microbia, Inc., and is headquartered in Boston, Massachusetts.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-IRWD
|
$5.62
|
29.1% Upside
|
Undervalued
|
$6.10
|
40.2% Upside
|
Undervalued
|
Great
|
0.0%
|
October 29, 2026
|
5.4x
|
1.8x
|
720.4 M
|
1.015 B
|
36.2%
|
82.8%
|
-2.0
|
142.9%
|
